MYELODYSPLASTIC SYNDROME (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROME (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for fanconi anemia: gentler transplant may reduce side effects
Disease control Recruiting nowThis study tests a stem cell transplant using lower doses of chemotherapy for people with Fanconi anemia who don't have a perfectly matched donor. The goal is to reduce serious side effects while still helping the body accept new blood-forming cells. About 70 participants will re…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated May 26, 2026 02:33 UTC
-
New cord blood combo could boost transplants for bone marrow diseases
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for people with severe aplastic anemia or a related bone marrow disease called MDS. Participants get a mix of stem cells from a family member and specially grown cord blood cells from an unrelated donor to help the new cells …
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated May 26, 2026 02:33 UTC
-
New drug CLN-049 targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called CLN-049 in about 60 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. CLN-049 is designed to help the body's immune cells attack cancer cells. The main goals …
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 02:32 UTC
-
New combo therapy aims to fight advanced breast cancer and melanoma
Disease control Recruiting nowThis early-phase study is testing a combination of two drugs, alpelisib and pembrolizumab, in people with metastatic breast cancer or melanoma that has spread to the brain. The main goal is to find a safe dose and check for side effects. About 50 adults whose cancer has not respo…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 02:31 UTC
-
Could a pill replace needles for MDS treatment?
Disease control Recruiting nowThis early-stage study tests an oral combination drug (ASTX030) for people with myelodysplastic syndrome (MDS), a blood disorder. The goal is to see if the pill form works as well as the standard injection. About 40 adults with MDS will take the drug by mouth, and researchers wil…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New antibody combo aims to target leukemia stem cells
Disease control Recruiting nowThis study tests a new drug called nadunolimab combined with standard treatments (azacitidine, with or without venetoclax) in 40 adults with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to see if the combination is safe and can target leuk…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New study listens to patients with rare blood disorder
Knowledge-focused Recruiting nowThis study aims to understand the daily experiences, symptoms, and quality of life of 50 people in Japan with low-risk myelodysplastic syndrome (MDS) or unexplained anemia. Participants will fill out questionnaires and may be interviewed about their symptoms, treatment satisfacti…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC